Advertisement

Product › Details
Budesolv
![]() |
Status | 2018-10-19 development p3 start |
![]() |
Organisation | Marinomed Biotech AG (VSE: MARI) |
Marinomed Biotech AG. (10/19/18). "Press Release: Initiation of First Marinosolv Clinical Trial (Ph III)".
Marinomed Biotech AG is proud to announce the initiation of their Ph III clinical trial “BDS_18_01” with their first Marinosolv-based investigational medicinal product, “Budesolv 10 micrograms, nasal spray”. This nasal spray will be the first budesonide-based treatment for allergic rhinitis (hay fever) that delivers the active substance in dissolved form, thereby allowing treatment with a lower dose of budesonide than marketed products in a preservative-free configuration. The patent-protected development product will be tested for the indication of allergic rhinitis in the setting of the clinical research facility VCC (Vienna Challenge Chamber), the first and world-leading study center that performs clinical allergy trials under controlled and reproducible conditions in Vienna (www.vcc.at).
[Photo] The “Budesolv 10” study team during the initiation visit at the Vienna Challenge Chamber. Left to right: Dr. Reinhard Riedlsperger, Mag. Martina Görner, CRS Riedlsperger GmbH; Dr. Patrick Lemell, Dr. Petra Zieglmayer, Ing. Rene Zieglmayer, Vienna Challenge Chamber; Dr. Nicole Unger-Manhart, Dr. Eva Prieschl-Grassauer, Dr. Andreas Goessl, Mag. Sabine Grohmann, Marinomed Biotech AG
Record changed: 2019-02-01 |
Advertisement

More documents for glucocorticoid
- [1] Marinomed Biotech AG. (1/29/19). "Press Release: Marinomed Sets Offer Price at 75 Euro per Share (Adhoc-News)"....
- [2] Marinomed Biotech AG. (11/28/18). "Press Release: Viennese Biotech Company Marinomed Demonstrates the Benefits of Its Patented Marinosolv Technology"....
- [3] AstraZeneca plc. (12/5/16). "Press Release: AstraZeneca Completes Agreement With Cilag GmbH International for Rights to Rhinocort Aqua Outside the US"....
- [4] Bayer AG. (1/11/11). "Press Release: Evidence-based Review Published in JEADV. Methylprednisolone aceponate Provides Optimal Benefit-risk Ratio for the Treatment of Atopic Dermatitis in Children". Berlin....
- [5] Galapagos N.V.. (3/5/10). "Press Release: Galapagos Reports Record Revenues and Net Profit for 2009, Foresees Sustained Profitability". Mechelen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top